Skip to content
Angion Biomedica Corp

Angion Biomedica Corp

ANGION IS A LATE-STAGE CLINICAL COMPANY DEVELOPING SMALL MOLECULES TARGETING ACUTE ORGAN INJURY AND CHRONIC FIBROSIS

  • about
    • executive management
    • scientific advisory board
    • board of directors
  • our science
    • HGF/c-Met Pathway
    • Acute Kidney Injury
    • Acute Lung Injury
    • CNS Injury
  • pipeline
    • ANG-3777
    • ANG-3070
    • ROCK2 Inhibitor
    • CYP11B2 Inhibitor
  • Investors
    • stock information
      • stock quote & chart
    • press releases
    • events & presentations
    • financial information
      • SEC filings
    • governance
    • investor resources
      • investor contact
      • investor FAQs
      • email alerts
  • publications
  • careers
  • contact

Member Category: Scientific Advisory Board

Gregory P. Downey, MD

Gregory P. Downey, MD

Matthew Weir, MD

Matthew Weir, MD

Matthew Cooper, MD

Matthew Cooper, MD

Ken Newell, MD

Ken Newell, MD

Jack Boyd, MD

Jack Boyd, MD

Sumit Mohan, MD

Sumit Mohan, MD

Anupam Agarwal, MD

Anupam Agarwal, MD

Michael Koren, MD

Michael Koren, MD

Joseph Bonventre, MD

Joseph Bonventre, MD

CATEGORIES

  • RSL-HGF
  • RSL-ALI
  • Fibrosis
  • ROCKi
  • angion publications
  • RSL-AKI
  • events

CORPORATE ADDRESS

51 Charles Lindbergh Boulevard
Uniondale, NY 11553

Navigation

  • home
  • about
  • our science
  • pipeline
  • investors
  • publications
  • careers
  • contact

© 2021 Angion. All Rights Reserved.
Legal and Privacy Policy

NEW YORK | SAN FRANCISCO | BOSTON